Skip to content

Study · Not a test of the peptide alone · 2022

12 results

Cholinergic Neuron Targeting Nanosystem Delivering Hybrid Peptide for Combinatorial Mitochondrial Therapy in Alzheimer's Disease.

Qian K, Bao X, Li Y, Wang P, Guo Q, Yang P, Xu S, Yu F, Meng R, Cheng Y, Sheng D, Cao J and 7 more

Show all authors

Xu M, Wu J, Wang T, Wang Y, Xie Q, Lu W, Zhang Q

ACS nano15 Jul 2022Cited by 66 (Europe PMC)

PMID35839463 (opens in a new tab)DOI10.1021/acsnano.2c05795 (opens in a new tab)PepBankPUB-35839463
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone12

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Pharmacokinetics

    An FGL-modified nanosystem carrying the SS31-humanin hybrid peptide gave 4.8-fold enhanced accumulation in the brain.

    In plain wordsA targeted nanocarrier for a hybrid peptide that includes SS31 reached the brain 4.8-fold more strongly.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseBrain accumulation of the nanosystem
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    brain accumulation
    4.8 fold
    FGL-NP(Cit)/HNSS

    Source sentences

    Summary
    Meanwhile, based on fibroblast growth factor receptor 1(FGFR1) overexpression in both the blood-brain barrier and cholinergic neuron, an FGFR1 ligand-FGL peptide was modified on the nanosystem (FGL-NP(Cit)/HNSS) to achieve 4.8-fold enhanced accumulation in brain with preferred distribution into chol…
    1 context sentence
    Summary · context
    Therefore, we developed a multifunctional hybrid peptide HNSS composed of antioxidant peptide SS31 and neuroprotective peptide S14G-Humanin.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  2. 02AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Mechanism

    In 3xTg-AD mice, the nanosystem with the SS31-humanin hybrid peptide rescued mitochondrial dysfunction through the PGC-1α and STAT3 pathways.

    In plain wordsIn mice with Alzheimer-type disease, a nanocarrier with a hybrid peptide including SS31 rescued mitochondrial function.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseMitochondrial dysfunction
    Study

    mousen: not reported in source

    3xTg-AD mice
    Outcome group
    Mitochondrial function · Nervous system and cognition

    Source sentences

    Summary
    FGL-NP(Cit)/HNSS effectively rescued mitochondria dysfunction via the PGC-1α and STAT3 pathways, inhibited Aβ deposition and tau hyperphosphorylation, and ameliorated memory defects and cholinergic neuronal damage in 3xTg-AD mice.
    1 context sentence
    Summary · context
    Therefore, we developed a multifunctional hybrid peptide HNSS composed of antioxidant peptide SS31 and neuroprotective peptide S14G-Humanin.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  3. 03AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome

    In 3xTg-AD mice, the nanosystem with the SS31-humanin hybrid peptide inhibited Aβ deposition.

    In plain wordsIn mice with Alzheimer-type disease, a nanocarrier with a hybrid peptide including SS31 reduced Aβ deposits.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseAβ deposition
    Study

    mousen: not reported in source

    3xTg-AD mice
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    FGL-NP(Cit)/HNSS effectively rescued mitochondria dysfunction via the PGC-1α and STAT3 pathways, inhibited Aβ deposition and tau hyperphosphorylation, and ameliorated memory defects and cholinergic neuronal damage in 3xTg-AD mice.
    1 context sentence
    Summary · context
    Therefore, we developed a multifunctional hybrid peptide HNSS composed of antioxidant peptide SS31 and neuroprotective peptide S14G-Humanin.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  4. 04AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome

    In 3xTg-AD mice, the nanosystem with the SS31-humanin hybrid peptide inhibited tau hyperphosphorylation.

    In plain wordsIn mice with Alzheimer-type disease, a nanocarrier with a hybrid peptide including SS31 reduced tau changes.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseTau hyperphosphorylation
    Study

    mousen: not reported in source

    3xTg-AD mice
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    FGL-NP(Cit)/HNSS effectively rescued mitochondria dysfunction via the PGC-1α and STAT3 pathways, inhibited Aβ deposition and tau hyperphosphorylation, and ameliorated memory defects and cholinergic neuronal damage in 3xTg-AD mice.
    1 context sentence
    Summary · context
    Therefore, we developed a multifunctional hybrid peptide HNSS composed of antioxidant peptide SS31 and neuroprotective peptide S14G-Humanin.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  5. 05AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome

    In 3xTg-AD mice, the nanosystem with the SS31-humanin hybrid peptide ameliorated memory defects.

    In plain wordsIn mice with Alzheimer-type disease, a nanocarrier with a hybrid peptide including SS31 improved memory.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseMemory defects
    Study

    mousen: not reported in source

    3xTg-AD mice
    Outcome group
    Cognition and memory · Nervous system and cognition

    Source sentences

    Summary
    FGL-NP(Cit)/HNSS effectively rescued mitochondria dysfunction via the PGC-1α and STAT3 pathways, inhibited Aβ deposition and tau hyperphosphorylation, and ameliorated memory defects and cholinergic neuronal damage in 3xTg-AD mice.
    1 context sentence
    Summary · context
    Therefore, we developed a multifunctional hybrid peptide HNSS composed of antioxidant peptide SS31 and neuroprotective peptide S14G-Humanin.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  6. 06AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome

    In 3xTg-AD mice, the nanosystem with the SS31-humanin hybrid peptide ameliorated cholinergic neuronal damage.

    In plain wordsIn mice with Alzheimer-type disease, a nanocarrier with a hybrid peptide including SS31 reduced damage to cholinergic nerve cells.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseCholinergic neuronal damage
    Study

    mousen: not reported in source

    3xTg-AD mice
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    FGL-NP(Cit)/HNSS effectively rescued mitochondria dysfunction via the PGC-1α and STAT3 pathways, inhibited Aβ deposition and tau hyperphosphorylation, and ameliorated memory defects and cholinergic neuronal damage in 3xTg-AD mice.
    1 context sentence
    Summary · context
    Therefore, we developed a multifunctional hybrid peptide HNSS composed of antioxidant peptide SS31 and neuroprotective peptide S14G-Humanin.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  7. 07AnimalNot a test of Humanin aloneAnimal study (in vivo)Pharmacokinetics

    In mice, the FGL-modified nanosystem FGL-NP(Cit)/HNSS, carrying the hybrid peptide HNSS, achieved 4.8-fold enhanced accumulation in brain, with preferred distribution into cholinergic neurons in the diseased region.

    In plain wordsIn mice, a nanoparticle carrying a hybrid peptide with a humanin part reached the brain 4.8-fold more, mainly in cholinergic neurons.

    Peptide
    Humanin
    Outcome
    IncreaseBrain accumulation of nanosystem
    Study

    mousen: not reported in source

    3xTg-AD mice
    Outcome group
    Pharmacokinetics · Nervous system and cognition

    Measurements

    Brain accumulation enhancement
    4.8 fold
    FGL-NP(Cit)/HNSS

    Source sentences

    Summary
    Meanwhile, based on fibroblast growth factor receptor 1(FGFR1) overexpression in both the blood-brain barrier and cholinergic neuron, an FGFR1 ligand-FGL peptide was modified on the nanosystem (FGL-NP(Cit)/HNSS) to achieve 4.8-fold enhanced accumulation in brain with preferred distribution into chol…
    1 context sentence
    Summary · context
    Therefore, we developed a multifunctional hybrid peptide HNSS composed of antioxidant peptide SS31 and neuroprotective peptide S14G-Humanin.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

  8. 08AnimalNot a test of Humanin aloneAnimal study (in vivo)Mechanism

    In 3xTg-AD mice, FGL-NP(Cit)/HNSS, a nanosystem carrying the hybrid peptide HNSS, rescued mitochondrial dysfunction via the PGC-1α and STAT3 pathways.

    In plain wordsIn a mouse model of Alzheimer's disease, a nanoparticle carrying a hybrid peptide with a humanin part rescued mitochondrial dysfunction.

    Peptide
    Humanin
    Outcome
    IncreaseMitochondrial dysfunction rescue via PGC-1α and STAT3
    Study

    mousen: not reported in source

    3xTg-AD mice
    Outcome group
    Mitochondrial function · Nervous system and cognition

    Source sentences

    Summary
    FGL-NP(Cit)/HNSS effectively rescued mitochondria dysfunction via the PGC-1α and STAT3 pathways, inhibited Aβ deposition and tau hyperphosphorylation, and ameliorated memory defects and cholinergic neuronal damage in 3xTg-AD mice.
    1 context sentence
    Summary · context
    Therefore, we developed a multifunctional hybrid peptide HNSS composed of antioxidant peptide SS31 and neuroprotective peptide S14G-Humanin.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

  9. 09AnimalNot a test of Humanin aloneAnimal study (in vivo)Efficacy outcome

    In 3xTg-AD mice, FGL-NP(Cit)/HNSS inhibited Aβ deposition.

    In plain wordsIn a mouse model of Alzheimer's disease, a nanoparticle carrying a hybrid peptide with a humanin part reduced Aβ deposition.

    Peptide
    Humanin
    Outcome
    DecreaseAbeta deposition
    Study

    mousen: not reported in source

    3xTg-AD mice
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    FGL-NP(Cit)/HNSS effectively rescued mitochondria dysfunction via the PGC-1α and STAT3 pathways, inhibited Aβ deposition and tau hyperphosphorylation, and ameliorated memory defects and cholinergic neuronal damage in 3xTg-AD mice.
    1 context sentence
    Summary · context
    Therefore, we developed a multifunctional hybrid peptide HNSS composed of antioxidant peptide SS31 and neuroprotective peptide S14G-Humanin.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

  10. 10AnimalNot a test of Humanin aloneAnimal study (in vivo)Efficacy outcome

    In 3xTg-AD mice, FGL-NP(Cit)/HNSS inhibited tau hyperphosphorylation.

    In plain wordsIn a mouse model of Alzheimer's disease, a nanoparticle carrying a hybrid peptide with a humanin part reduced tau hyperphosphorylation.

    Peptide
    Humanin
    Outcome
    DecreaseTau hyperphosphorylation
    Study

    mousen: not reported in source

    3xTg-AD mice
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    FGL-NP(Cit)/HNSS effectively rescued mitochondria dysfunction via the PGC-1α and STAT3 pathways, inhibited Aβ deposition and tau hyperphosphorylation, and ameliorated memory defects and cholinergic neuronal damage in 3xTg-AD mice.
    1 context sentence
    Summary · context
    Therefore, we developed a multifunctional hybrid peptide HNSS composed of antioxidant peptide SS31 and neuroprotective peptide S14G-Humanin.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

  11. 11AnimalNot a test of Humanin aloneAnimal study (in vivo)Efficacy outcome

    In 3xTg-AD mice, FGL-NP(Cit)/HNSS ameliorated memory defects.

    In plain wordsIn a mouse model of Alzheimer's disease, a nanoparticle carrying a hybrid peptide with a humanin part improved memory defects.

    Peptide
    Humanin
    Outcome
    IncreaseMemory defects
    Study

    mousen: not reported in source

    3xTg-AD mice
    Outcome group
    Cognition and memory · Nervous system and cognition

    Source sentences

    Summary
    FGL-NP(Cit)/HNSS effectively rescued mitochondria dysfunction via the PGC-1α and STAT3 pathways, inhibited Aβ deposition and tau hyperphosphorylation, and ameliorated memory defects and cholinergic neuronal damage in 3xTg-AD mice.
    1 context sentence
    Summary · context
    Therefore, we developed a multifunctional hybrid peptide HNSS composed of antioxidant peptide SS31 and neuroprotective peptide S14G-Humanin.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

  12. 12AnimalNot a test of Humanin aloneAnimal study (in vivo)Efficacy outcome

    In 3xTg-AD mice, FGL-NP(Cit)/HNSS ameliorated cholinergic neuronal damage.

    In plain wordsIn a mouse model of Alzheimer's disease, a nanoparticle carrying a hybrid peptide with a humanin part reduced cholinergic neuronal damage.

    Peptide
    Humanin
    Outcome
    DecreaseCholinergic neuronal damage
    Study

    mousen: not reported in source

    3xTg-AD mice
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    FGL-NP(Cit)/HNSS effectively rescued mitochondria dysfunction via the PGC-1α and STAT3 pathways, inhibited Aβ deposition and tau hyperphosphorylation, and ameliorated memory defects and cholinergic neuronal damage in 3xTg-AD mice.
    1 context sentence
    Summary · context
    Therefore, we developed a multifunctional hybrid peptide HNSS composed of antioxidant peptide SS31 and neuroprotective peptide S14G-Humanin.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 18Current

    28 Oct 2026, 02:02 UTC

    The same notice was added 15 times, first on 13 Oct 2026, 21:44 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    13 Oct 2026, 16:31 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    10 Oct 2026, 08:19 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.